Michael Collins

Michael Collins

Auto-generated profile, based on publicly available information

Michael Collins

Department of Pharmacology University of Cambridge Cambridge UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2026 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
APAbigail Pearce
Abigail Pearce
XHXianglin Huang
Xianglin Huang
TRTheo Redfern‐Nichols
Theo Redfern‐Nichols
CSClaudia M. Sisk
Claudia M. Sisk
DSDewi Safitri
Dewi Safitri
GLGraham Ladds
Graham Ladds
The teaching of pharmacology includes a fundamental understanding of ligand binding; how it is measured and how it is calculated. We sought to modernize the techniques by which ligand affinity is determined by undergraduate students and introduce them to parameter estimation through curve fitting. We taught a NanoBRET ligand binding assay to student cohorts completing their second year of undergraduate study in Natural Sciences (71 and 61 students in 2024 and 2025 respectively). The aim was to measure the affinity of fluorescent and unlabeled ligands for the β 2 ‐adrenoceptor in live cells. Affinities were then calculated from their data using a custom Microsoft Excel spreadsheet. This series of practical classes was well received by students, with most students able to follow the protocol and successfully determine ligand affinities. Furthermore, students recognized the benefit of the practical class for their education, confirming they felt it improved their understanding of how ligand affinity is calculated. We also demonstrated that this protocol could be scaled up to accommodate larger class sizes (class of 367 students studying medicine and veterinary sciences).

17 September 2025 in bioRxiv
Verified
Preprint
Open access
APAbigail Pearce
Abigail Pearce
MCMichael Collins
Michael Collins
ADAaron Dexter
Aaron Dexter
ASAnjana Saji
Anjana Saji
CSClaudia M Sisk
Claudia M Sisk
GLGraham Ladds
Graham Ladds
Animal use in research extends beyond the use of animal models to study physiology and disease. Many aspects of in vitro research use reagents derived from animals, most prolifically the use of foetal bovine serum (FBS) in growth media for cellular models. With the aim to reduce animal use, we investigated the effect of reduced FBS culture conditions on cell growth, as well as different stages of G protein-coupled receptor (GPCR) signalling, a wide area of research which might therefore impact many groups. We identified little differences on cell growth or GPCR signalling when reducing culture FBS percentage from 10% to 5%, using assays ranging from receptor activation to downstream transcription factors stimulation. In addition to diminishing animal use, the reduction of FBS use will also have economic and environmental benefits, which we hope will be of benefit to the wider research community.